|Page (1) of 1 - 07/14/17||email article||print page|
Cystic Fibrosis Pipeline Drug Therapeutics Development H1 2017
PUNE, India, July 14, 2017 /PRNewswire-iReach/ -- Cystic Fibrosis pipeline drug therapeutics review H1 2017 provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.
Complete Report on Cystic Fibrosis Drug Pipeline Therapeutics Review H1 2017 Available at http://www.reportsnreports.com/reports/992880-cystic-fibrosis-pipeline-review-h1-2017.html
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 25, 27, 1, 55, 25 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 2, 4, 7 and 1 molecule respectively. Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Purchase Cystic Fibrosis Pipeline Review H1 2017 Report of 383 Pages at http://www.reportsnreports.com/purchase.aspx?name=992880 .
Cystic Fibrosis Pipeline Drug Development by Companies Analyzed in Report are Achaogen Inc, Actelion Ltd, Advanced Inhalation Therapies (AIT) Ltd, Aeolus Pharmaceuticals Inc, Alaxia SAS, AlgiPharma AS, AmpliPhi Biosciences Corp, Apteeus, Arch Biopartners Inc, Arcturus Therapeutics Inc, Aridis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim GmbH, Catabasis Pharmaceuticals Inc, Celtaxsys Inc, Chiesi Farmaceutici SpA, Cilian AG, Concert Pharmaceuticals Inc, CRISPR Therapeutics, Cyclacel Pharmaceuticals Inc, DiscoveryBiomed Inc, Editas Medicine Inc, Eloxx Pharmaceuticals Ltd, Enterprise Therapeutics Ltd, Errant Gene Therapeutics LLC, ethris GmbH, Galapagos NV, Gilead Sciences Inc, GlaxoSmithKline Plc, Grifols SA, Grupo Praxis Pharmaceutical SA, Horizon Pharma Plc, ID Pharma Co Ltd, Immun System IMS AB, Insmed Inc, Invion Ltd, Ionis Pharmaceuticals Inc, JHL Biotech Inc, Kamada Ltd, Kyorin Pharmaceutical Co Ltd, La Jolla Pharmaceutical Company, Lakewood-Amedex Inc, Lamellar Biomedical Ltd, Laurent Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Mast Therapeutics Inc, Merck & Co Inc, Microbion Corp, Mucokinetica Ltd, Novabiotics Ltd, Novartis AG, OSE Immunotherapeutics, Paranta Biosciences Ltd, Parion Sciences Inc, Pfizer Inc, Pharmaxis Ltd, PhaseBio Pharmaceuticals Inc, Polyphor Ltd, Progenra Inc, ProMetic Life Sciences Inc, ProQR Therapeutics NV, Protalix BioTherapeutics Inc, Proteostasis Therapeutics Inc, Pulmatrix Inc, RaNA Therapeutics Inc, ReveraGen BioPharma Inc, Savara Inc, Shionogi & Co Ltd, SOM Biotech SL, Synedgen Inc, Synovo GmbH, Vanda Pharmaceuticals Inc, Verona Pharma Plc, Vertex Pharmaceuticals Inc, Xenetic Biosciences Inc.
Related Report on Cystic Fibrosis:
The report "EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025" provides an overview of the risk factors, comorbidities, and the global and historical trends for CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiological forecast for the diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality based on county-specific registry data. Moreover this report provides the in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. According to the forecast adjusted for underestimation of registry data, the diagnosed incident cases of CF in the 7MM will decrease from 2,217 cases in 2015 to 2,074 cases in 2025, at an AGR of negative 0.64%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest. In the 7MM, based on registry data, our epidemiologists forecast that the diagnosed prevalent cases of CF will increase from 63,571 cases in 2015 to 73,368 cases in 2025, at an AGR of 1.54%. The US will have the highest number of diagnosed prevalent cases of CF among the 7MM throughout the forecast period, while Spain will have the lowest.
Browse Pharmaceutical Market Research Report at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Media Contact: Ritesh Tiwari, ReportsnReports, +1-888-391-5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
Copyright 2014 PR Newswire. All Rights Reserved
Related Keywords:Pro AV, Presentors, Business Issues, Presentation, Medicine, Disease, Surgery, Medication, Science, Medical, Biology,